CME

Host: Prof. Melanie Davies, MD

Guest: Chantal Mathieu, MD, PhD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Chantal Mathieu, MD, PhD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Prof. Melanie Davies, MD

Guest: Athena Philis-Tsimikas, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Prof. Melanie Davies, MD

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Fortunato Ciardiello, MD, PhD

Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Fortunato Ciardiello, MD, PhD

Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Fortunato Ciardiello, MD, PhD

Host: Jenny Seligmann, MBChB, PhD

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.